A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma

Cancer Immunol Immunother. 2019 Apr;68(4):619-629. doi: 10.1007/s00262-019-02308-w. Epub 2019 Feb 6.

¹ Comprehensive Cancer Center, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, N924 Doan Hall 410 W. 10th Ave, Columbus, OH, 43210-1228, USA.
² Medical Oncology, Department of Internal Medicine, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH, USA.
³ Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
⁴ Promedica Toledo Hospital, Toledo, OH, USA.
⁵ Division of Rheumatology and Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
⁶ Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
⁷ Department of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, OH, USA.
⁸ Hematology, Department of Internal Medicine, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH, USA.
⁹ Comprehensive Cancer Center, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, N924 Doan Hall 410 W. 10th Ave, Columbus, OH, 43210-1228, USA. william.carson@osumc.edu.
¹⁰ Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA. william.carson@osumc.edu.

No abstract available

Publication types